Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. (Nasdaq: ESLA) is a clinical-stage biopharmaceutical company focused on cancer immunotherapy research and development. The company reached the public markets through a SPAC combination, trading on the Nasdaq under the ESLA ticker. On October 5, 2023, the company filed a Form 25-NSE with the Securities and Exchange Commission, initiating the voluntary withdrawal of its Class A common stock from Nasdaq listing and deregistration under Section 12(b) of the Securities Exchange Act, effectively concluding its tenure as a publicly listed entity in the biopharma sector. For full filing history, deal data, and SPAC analytics on Estrella Immunopharma and hundreds of other transactions, sign up for complete access at SpacDesk.